Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms.
about
Physiological parameters for oral delivery and in vitro testingPerformance Parameters and Characterizations of Nanocrystals: A Brief ReviewRelease of a Poorly Soluble Drug from Hydrophobically Modified Poly (Acrylic Acid) in Simulated Intestinal FluidsStability of the major allergen Brazil nut 2S albumin (Ber e 1) to physiologically relevant in vitro gastrointestinal digestion.The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity.In vitro and in vivo evaluation of glibenclamide in solid dispersion systems.Formation of reactive aldehydes (MDA, HHE, HNE) during the digestion of cod liver oil: comparison of human and porcine in vitro digestion models.Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesPhysicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine.The use of biorelevant dissolution media to forecast the in vivo performance of a drug.The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing.Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems.Analytical methods for dissolution testing of nanosized drugs.Using droplet-based microfluidic technology to study the precipitation of a poorly water-soluble weakly basic drug upon a pH-shift.Cyclodextrin-based pharmaceutics: past, present and future.Development and validation of a discriminative dissolution test for betamethasone sodium phosphate and betamethasone dipropionate intramuscular injectable suspension.Disintegration of solid foods in human stomach.A model for calcium permeation into small intestineRole of medium-chain fatty acids in the emulsification mechanistics of self-micro-emulsifying lipid formulationsConcurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline.Mathematical Models to Explore Potential Effects of Supersaturation and Precipitation on Oral Bioavailability of Poorly Soluble Drugs.Nanosuspensions: a promising drug delivery strategy.Ultra rapidly dissolving repaglinide nanosized crystals prepared via bottom-up and top-down approach: influence of food on pharmacokinetics behavior.Human Gastrointestinal Juices Intended for Use in In Vitro Digestion Models.Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers.Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling.Impact of Micellar Surfactant on Supersaturation and Insight into Solubilization Mechanisms in Supersaturated Solutions of Atazanavir.Colon drug delivery.Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).Prediction of human pharmacokinetics--gastrointestinal absorption.Engineering and characterization of simplified vaginal and seminal fluid simulants.Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effectspH-Dependent Solubility and Dissolution Behavior of Carvedilol--Case Example of a Weakly Basic BCS Class II Drug.Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel.Drug absorption modeling as a tool to define the strategy in clinical formulation development.Dissolution of pentoxifylline from extended release formulations. Researches concerning development of a biorelevant test.Biomagnetic methods: technologies applied to pharmaceutical research.Drug delivery strategies for poorly water-soluble drugs: the industrial perspective.Biorelevant in-vitro performance testing of orally administered dosage forms.
P2860
Q27687044-75CAEC5F-9DE9-4F6F-ADE8-6F74FE1D13BAQ28077580-75CD6DC0-6745-46EF-9A4F-EF84D0C6644CQ28550369-41562859-84C7-481C-B37D-FE29D011D2F5Q30349998-811FF9DE-8DCD-41A0-85B8-0E07D0339506Q30381972-5D8D5990-072C-4910-8364-20FE36917A95Q33205350-8D733613-A040-4B25-B56E-0F9B2421B1A1Q33467115-71C1546C-BF69-45AB-A701-AEADB4E6C0C2Q33571451-920FE4E9-447A-4D8D-BF76-6ECDC6200662Q33683206-F9765C50-F8E0-457C-80A0-0975312E293CQ33694804-10C91490-D2AD-442A-BA97-62040123CECFQ33954607-9F08F0E6-6D15-40CE-B77D-4CDF11E55EF9Q34203174-15DC0DD1-86A4-414D-A316-77D82F468A0DQ34285667-78E1DEEF-9649-4FF5-B401-F3970C9E4CAAQ34299947-464222B7-2FCE-4117-891B-D179B461F028Q34478120-0A8B6D72-D28E-4055-9913-EE01E2E7B363Q34552997-BB6B0FAE-F0A7-46A0-BD68-1CCE71885C42Q34570631-9873C566-1E1A-4878-A487-88B40D5412A0Q34788774-F1D2A52A-7FD3-44F5-AEBE-072949A639BAQ35154376-056D33C2-45FE-412B-A16C-51AD4E16F9EFQ35538681-DBAC4FA4-38CE-42BB-9168-7C1A3F4EB9C6Q35580773-1CCE4452-5EF7-4CAC-8DE1-3EBE27E8BB97Q35768399-198DAB8C-BAF8-461C-A475-31C4820D4B47Q35826447-E98401A9-F951-4A3C-AB48-DCBF29EA2EF4Q35868308-93DB68A6-D01A-4527-AC6C-AE47784F0BA9Q35920619-ECA19822-96EB-473E-84D2-2CB710CC4784Q35940550-3FE7264E-D9D8-4D3E-B71D-A3274039F40EQ36232481-929FEADD-598D-43C7-9FC2-9EEC95AFBA50Q36326329-90A774E0-A0ED-409F-8127-270B38371022Q36349704-BFD979CB-0A7E-4710-9DA7-A6B0245C81A2Q36885229-3B4C58CE-E44F-4D8A-8396-E00DB463B94BQ36885247-9A6D8461-C32F-40D0-A10D-2EC15F1446E5Q36890847-097F3B3F-558A-4C88-86D5-B7EFBC5D0AECQ37149095-B144176F-B41B-4448-B699-71F6DECEB446Q37174993-5890A286-444E-4DCF-AEAF-CD24B993E30FQ37226139-D21774AC-47E4-4C8B-8FAC-36218513FFDAQ37254283-A5348E37-3517-41D6-86C6-2FAE84760938Q37622445-14416C89-27A3-4FDD-80E5-60CCC603D353Q37800414-5169CBF5-7960-4B32-B1CA-801ACA020481Q37927093-087325CA-B8C0-4651-8128-C6F78F9BDC3EQ38017705-96D812B4-E413-4E51-A1BE-D6E19D6FF3E4
P2860
Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Dissolution testing as a progn ...... mmediate release dosage forms.
@en
type
label
Dissolution testing as a progn ...... mmediate release dosage forms.
@en
prefLabel
Dissolution testing as a progn ...... mmediate release dosage forms.
@en
P2093
P356
P1476
Dissolution testing as a progn ...... mmediate release dosage forms.
@en
P2093
P356
10.1023/A:1011984216775
P577
1998-01-01T00:00:00Z